Media headlines about Masimo Corporation (NASDAQ:MASI) have trended somewhat positive on Monday, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Masimo Corporation earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 46.5331782741374 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Electroencephalography (EEG) and Electromyography (EMG) Market to be Worth US$2.4 bn by the End of 2024 (mynewsdesk.com)
- Newborn Screening Market Plan, Supply and Revenue to 2023 (medgadget.com)
- Masimo (MASI) Launches Trace Data and Reporting Tool in US – Nasdaq (nasdaq.com)
- Head-To-Head Analysis: Apollo Endosurgery (APEN) & Masimo Corporation (MASI) (americanbankingnews.com)
- Masimo Corp. breached its 50 day moving average in a Bearish Manner : MASI-US : October 4, 2017 (finance.yahoo.com)
MASI has been the subject of a number of recent research reports. Roth Capital increased their price objective on shares of Masimo Corporation from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research downgraded shares of Masimo Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Stifel Nicolaus initiated coverage on shares of Masimo Corporation in a research note on Monday, July 10th. They set a “buy” rating and a $105.00 price objective for the company. BidaskClub upgraded shares of Masimo Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, July 12th. Finally, BTIG Research upgraded shares of Masimo Corporation from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Monday, August 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. Masimo Corporation presently has an average rating of “Hold” and an average price target of $97.00.
Masimo Corporation (NASDAQ:MASI) opened at 87.14 on Monday. The firm has a market capitalization of $4.53 billion, a P/E ratio of 14.28 and a beta of 0.82. The stock’s 50 day moving average is $85.34 and its 200-day moving average is $90.19. Masimo Corporation has a 1-year low of $53.78 and a 1-year high of $104.71.
Masimo Corporation (NASDAQ:MASI) last released its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.12. Masimo Corporation had a net margin of 45.90% and a return on equity of 23.45%. The business had revenue of $192.90 million for the quarter, compared to analysts’ expectations of $189.03 million. During the same period in the previous year, the company earned $0.57 earnings per share. The firm’s revenue for the quarter was up 11.8% compared to the same quarter last year. Analysts forecast that Masimo Corporation will post $2.80 EPS for the current year.
In related news, COO Anand Sampath sold 40,000 shares of the business’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $92.00, for a total transaction of $3,680,000.00. Following the transaction, the chief operating officer now directly owns 20,000 shares in the company, valued at $1,840,000. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Sanford Fitch sold 11,000 shares of the business’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $87.25, for a total transaction of $959,750.00. Following the transaction, the director now owns 72,249 shares in the company, valued at $6,303,725.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 112,000 shares of company stock worth $10,444,090. 16.60% of the stock is owned by corporate insiders.
WARNING: “Masimo Corporation (MASI) Earning Somewhat Favorable Media Coverage, Analysis Finds” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://ledgergazette.com/2017/10/09/masimo-corporation-masi-earning-somewhat-favorable-media-coverage-analysis-finds.html.
Masimo Corporation Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corporation and related companies with MarketBeat.com's FREE daily email newsletter.